Altre lingue Enzychem Lifesciences Corporation

Azioni

A183490

KR7183490002

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 17/05/2024			Variaz. 5gg	Var. 1 gen.
1.992 ^KRW	+0,71%		+1,68%	+9,57%

05/04	Enzychem Lifesciences Corporation (KOSDAQ:A183490) annuncia un programma di riacquisto di azioni per un valore di 10.000 milioni di KRW.	CI
05/04	Enzychem Lifesciences Corporation autorizza un piano di riacquisto.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Enzychem Lifesciences Corporation announces an Equity Buyback for KRW 10,000 million worth of its shares.	05/04
Enzychem Lifesciences Corporation authorizes a Buyback Plan.	05/04
Enzychem Lifesciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Enzychem Lifesciences Announces Completion of Clinical Study Report for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis	09/03/22
Cadila Healthcare Limited Entered into A Definitive Agreement with Shilpa Medicare Limited and Enzychem Lifesciences	02/02/22
Hanmi Pharma to Manufacture COVID-19 Vaccine Developed by India's Zydus Cadila	12/01/22
Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries with Enzychem Lifesciences	04/01/22
Enzychem Lifesciences Corporation to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea	26/11/21
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot	24/11/21
Enzychem Lifesciences Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis	08/11/21
Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis	20/10/21
Enzychem Lifesciences Announces Database Lock for Phase 2 Study of Ec-18 in Chemoradiation-Induced Oral Mucositis	13/09/21
Neutropenia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight \| Spectrum Pharmaceuticals, Cellerant Therapeutics, X4 Pharmaceuticals, Tanvex Biopharma, Enzychem Lifesciences	12/05/21
Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program	20/04/21
Enzychem Lifesciences Announces Last Patient Enrolled in Stage 2 of Phase 2 Study of EC-18 in Chemoradiation Induced Oral Mucositis	06/04/21
Enzychem Lifesciences Corporation announced that it has received KRW 6.5006487 billion in funding	08/03/21
Enzychem Lifesciences Corporation announced that it has received KRW 23.5014976 billion in funding	03/03/21
Enzychem Lifesciences Corporation announced that it expects to receive KRW 6.5006487 billion in funding	26/02/21
Enzychem Lifesciences Corporation announced that it expects to receive KRW 23.5014976 billion in funding	23/02/21
Enzychem Lifesciences Corporation announced that it has received KRW 50 billion in funding from Mirae Asset Daewoo Co., Ltd., Investment Arm, Kiwoom Securities Co., Ltd., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm, DB Financial Investment Co.,Ltd., Investment Arm	16/11/20

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Enzychem Lifesciences Corporation

Azioni

A183490

KR7183490002

Altre lingue

Filtri